How the War in Iran Is Threatening America’s Drug Supply - And Your Wallet

The conflict between the US, Israel, and Iran has escalated dramatically in recent weeks, with Iran’s moves around the Strait of Hormuz sending shockwaves far beyond oil markets. Most Americans are focused on gas prices, but there’s a quieter, and potentially more painful, ripple effect that could hit pharmacies across the country: generic drugs.

Nearly half of all generic prescriptions filled in the United States come from India. Those drugs depend on the very same maritime chokepoint that’s now in turmoil. Here’s exactly how the war could drive up prices and create shortages for the medicines millions of Americans rely on every day.

The Strait of Hormuz is Not Just an Oil Story

The Strait of Hormuz handles roughly 20% of the world’s oil trade. Iran’s has threatened to close or severely restrict it in response to US and Israeli actions, creating immediate chaos for shipping.

India - the “pharmacy of the world” - imports about 50% of its crude oil through this route. That oil doesn’t just fuel factories; it becomes the petrochemical feedstocks essential to drug manufacturing: solvents, plastics, packaging materials, glycerin (used in countless formulations), and phenols (key building blocks). Many active pharmaceutical ingredients (APIs) and intermediates also route through Gulf logistics hubs like Dubai before reaching Indian plants.

When the strait tightens, everything gets more expensive and slower:

- Air freight rates out of India have already surged 200–350% on key routes.

- Sea shipments face canceled sailings, rerouting around Africa, trapped containers, and skyrocketing insurance.

- Refrigerated cargo — critical for temperature-sensitive drugs - is at special risk of delays and cold-chain failures.

India Supplies 47% of US Generics - And Generics Are 90% of Prescriptions

India’s big players (Sun Pharma, Dr. Reddy’s, Lupin, and others) ship billions of dollars worth of finished generic tablets and capsules to the US every year. We’re talking:

- Metformin and other diabetes drugs

- Statins for cholesterol

- Blood pressure medications like metoprolol

- Common antibiotics (amoxicillin, etc.)

- Pain relievers and blood thinners

These are the everyday, low-cost medicines that keep chronic conditions under control for tens of millions of Americans. Because generics operate on razor-thin margins, even modest cost increases get passed to pharmacies, insurers, and patients - or lead manufacturers to deprioritize low-profit lines altogether, leading to shortages.

Buffers Exist - But They’re Not Infinite

US distributors typically hold 30–60 days of inventory. Some Indian manufacturers report 3–6 months of raw materials and finished product on hand.

But experts warn that sustained disruption could trigger shortages within 4–6 weeks, starting with high-volume, high-demand generics. Higher oil and energy prices also raise overall manufacturing costs across the board, squeezing the entire generic sector hardest because it lacks the pricing power of branded drugs.

The war is already inflating petrochemical prices and disrupting chemical supply chains that Iran itself helped anchor (Iran is a major producer of solvents and intermediates). Those knock-on effects will compound shipping issues and make reshoring or diversification even more urgent.

Why This Hits Generics Harder Than Branded Drugs

Branded pharmaceuticals often have greater margins and more flexible pricing. Generics don’t. When freight, energy, and raw-material costs spike, generic makers face a brutal choice: absorb the hit (and lose money), raise prices (and risk losing contracts), or cut production of less-profitable SKUs. The result? Spot shortages and gradual price creep that eventually shows up at the pharmacy counter or in higher insurance premiums.

What Patients and Policymakers Should Watch

If the conflict drags on:

- Expect upward pressure on prices for the most common chronic-disease generics.

- Watch for early signals in antibiotics, statins, and diabetes medications.

- Cold-chain biologics and certain injectables could face separate logistics headaches.

This isn’t hypothetical fear-mongering. The same dynamics played out (on smaller scales) during the Red Sea disruptions and COVID-era API shortages. The difference now is the scale of the energy chokepoint involved.

The good news? Post-COVID awareness has led to more redundancy and strategic stockpiles than before. The bad news? America’s dependence on a single country (India) for nearly half its generics - itself dependent on a single strait - remains a glaring vulnerability.

Time to Build Real Resilience

The war in Iran is a brutal reminder that geopolitics and medicine are more intertwined than most realize. For patients, the near-term advice is simple: don’t panic-buy, but talk to your doctor or pharmacist about 90-day supplies where possible and stay alert to any sudden price jumps or availability issues.

For the industry and Washington, the message is louder - accelerate reshoring incentives, diversify API sources beyond Asia, and treat pharmaceutical supply-chain security with the same urgency we give to semiconductors or rare earths.

Your blood pressure pill, your statin, your diabetes medication - they all just became part of the Middle East story whether you knew it or not. The longer the strait stays contested, the more Americans will feel it in their medicine cabinets and their wallets.

What do you think - should the US prioritize domestic generic manufacturing with the same intensity we’ve applied to chips and EVs?

The Patent Cliff Is Real —What Growth-Stage Biopharma CEOs Should Do Now

The patent cliff gets talked about as a Big Pharma problem. Humira's biosimilar wave. Roche navigating the loss of exclusivity on Perjeta, Kadcyla, and Ocrevus. AbbVie pivoting its entire immunology and neuroscience franchise to replace hundreds of billions in at-risk revenue. Merck facing USD18 billion in patent-driven revenue losses over the next five years — a pressure so acute it nearly drove a USD30 billion acquisition of Revolution Medicines in January 2026. 

But if you are the CEO of a growth-stage biopharma company, the patent cliff is not their problem. It is your opportunity. And the window to position yourself for it is right now.

Here is why — and what to do about it.

The Scale of the Opportunity

The numbers are hard to overstate. Between USD 200 and USD 400 billion in branded pharmaceutical revenue will lose patent protection between 2025 and 2030 — including Keytruda (USD 25 billion), Eliquis (USD 12 billion), and Stelara (USD 10.9 billion). Nearly 70 blockbuster drugs are losing exclusivity in this window. The scale is unprecedented.

Large acquirers — under intense board pressure to replace that revenue — have already accelerated M&A activity dramatically. IQVIA confirms that M&A spend in biopharma nearly doubled in 2025, with nine acquisitions exceeding USD 10 billion — the highest concentration of mega-deals on record. ING forecasts that deal activity will continue to accelerate in 2026, driven by the patent cliff, lower interest rates, and growing appetite for obesity drug and AI-enabled platform acquisitions. 

That capital is looking for assets to acquire, platforms to license, and operators to partner with. If your company is in the right therapeutic area, has a credible development or commercialization story, and is operationally well-run — you are a potential target. The question is whether you are visible and ready when the conversation happens.

Most growth-stage companies are not. Not because they lack the science, but because they have not done the strategic work to position themselves for this moment.

Know Your Acquirer Before They Know You

The first thing I tell growth-stage biopharma CEOs in today's environment is this: map your acquirer landscape now, not when you get an inbound call.

Who are the five to ten large pharma or specialty pharma companies most likely to acquire a company in your therapeutic area, at your stage, with your modality? What are their pipeline gaps? What patent expirations are they most exposed to? What is their M&A track record — do they integrate well or not?

Merck's pursuit of Revolution Medicines was not opportunistic. It was strategic and deliberate — driven by a specific, quantified revenue gap that Merck's board had been tracking for years. Revolution was on Merck's radar long before the Financial Times reported the USD 28–32 billion talks in January 2026. 

Understanding your likely acquirers in depth — their strategic priorities, their cultural DNA, their preferred deal structures — gives you three advantages: you can proactively build relationships before a process begins, you can shape your development and commercial strategy to align with what acquirers will value, and you will be a significantly better negotiator when the time comes.

This work takes months to do properly. Start now.

Build for Acquirability, Not Just Approvability

The default orientation of most growth-stage biopharma companies is regulatory: get the asset approved. That is necessary, but not sufficient.

Acquirability is a different standard. It means: can a large acquirer integrate your asset into their infrastructure and make the economics work? That requires clean CMC, a credible supply chain, a market access strategy that survives payer scrutiny, and an organization that can operate under new ownership without losing the key people who built it.

I have seen deals fail at late-stage diligence because of CMC issues that were known but not prioritized. I have seen term sheets retracted because the reimbursement story did not hold up under scrutiny. These are fixable problems — but only if you address them before a potential acquirer finds them first.

Conduct a rigorous self-diligence exercise at least 18 months before you expect to be in a process. Fix what you find.

Capitalize on Capability Gaps, Not Just Asset Gaps

The most important shift in biopharma M&A right now is the move from asset acquisitions to capability acquisitions. Large acquirers are not just looking for molecules — they are looking for platforms, manufacturing know-how, delivery technology, and commercial readiness that they cannot build fast enough internally. IQVIA's 2025 review confirms that buyers are prioritizing "quality, late-stage assets, and strategic focus" — meaning differentiated platforms and credible commercial potential command the largest premiums. 

If you have a novel drug delivery platform, a proprietary manufacturing process, or a commercially attractive asset — that capability has strategic value well beyond your current pipeline.

Make sure your investor materials, your corporate narrative, and your business development conversations explicitly articulate the capability, not just the asset. Many growth-stage companies bury their most strategically valuable attributes in the appendix of their pitch deck.

Raise Capital From Strategic Investors Now

The capital markets have improved, and strategic investors — corporate venture arms of large pharma, specialty pharma-focused funds, and crossover investors — are actively deploying capital into growth-stage biopharma right now.

A strategic investment is not just capital. It is a relationship, a validation signal, and often the first step in an acquisition process. Roche, AbbVie, Pfizer, and others all have active corporate venture programs specifically designed to build acquisition optionality.

If your current cap table is exclusively financial investors, consider a strategic round — not because you need the money, but because of who comes with it.

What to Avoid

Two pitfalls are particularly common for growth-stage CEOs navigating this environment.

Do not optimize for a valuation that kills the deal. The collapsed Merck/Revolution Medicines talks are a textbook example. Revolution Medicines' stock fell 22% the day the deal collapsed — wiping out much of the 47% rally that had built on acquisition speculation. A deal that closes at a fair valuation and integrates successfully creates more long-term value for founders, employees, and patients than a deal that fails over a valuation gap.

Do not wait for the perfect moment. The companies that will capture the most value from the current M&A cycle are the ones doing the strategic preparation today — not the ones who start scrambling when the inbound call arrives. With M&A spend nearly doubling in 2025 and ING forecasting further acceleration in 2026, the cycle is already well underway.

The patent cliff is reshaping the entire biopharma landscape. For growth-stage companies with the right assets, the right capabilities, and the right preparation, it represents a generational opportunity.

At Katogen, we help growth-stage biopharma CEOs navigate exactly these moments — from strategic positioning and acquirer mapping to capital raise preparation and transaction advisory — grounded in 35+ years of operator experience, 17 acquisitions, and USD 4B+ raised.

Why Biosimilar Companies Are Leaving Money on the Table in Market Access

The biosimilar market has generated over USD56.2 billion in savings for America's patients and the U.S. healthcare system since 2015. The FDA approved a record 18 biosimilars in 2025 — across oncology, immunology, ophthalmology, and endocrinology. And in the fastest-growing categories biosimilars have already captured 81% market share within five years of launch. 

The opportunity has never been larger. The execution has never been more complex.

And yet many biosimilar companies — including well-funded, scientifically sophisticated ones — are systematically underperforming on market access. Not because their products are inferior. Because their market access strategy was built too late, designed too narrowly, and executed without understanding how payer dynamics have fundamentally changed.

Here is what is going wrong, and how to fix it.

The Core Mistake: Treating Market Access as a Launch Activity

The most common and most costly market access mistake in biosimilars is treating payer strategy as something you build in the twelve months before launch.

By the time you are filing your BLA, your market access architecture should already be in place. Payer relationships take years to develop. Formulary positioning requires evidence packages that take time to build. Reimbursement modeling — particularly in the Medicare Part D context — requires understanding pricing dynamics that shift every budget cycle.

If your market access team is being hired as you approach your PDUFA date, you are already behind.

Underestimating PBM Consolidation

The three largest PBMs — CVS Caremark, Express Scripts, and OptumRx — control formulary access for the majority of commercially insured lives in the United States. Their consolidation has created an environment where formulary exclusions are not the exception — they are the strategy. Express Scripts alone added 129 new formulary exclusions in 2026.

Step therapy requirements, site-of-care steering, and formulary exclusions are actively being used to manage biosimilar uptake in ways that are not always intuitive. A biosimilar that wins on price may still lose on access if the PBM has a rebate relationship with the reference biologic manufacturer that makes formulary exclusion economically rational for them.

But there is a newer and increasingly important dynamic: PBMs are now actively preferring their own affiliated private-label biosimilars over third-party biosimilars on their formularies. CVS Caremark's Cordavis, for example, is a direct commercial entity competing with independent biosimilar manufacturers for formulary position within the same PBM's book of business. This is not a theoretical risk — it is already reshaping formulary decisions in adalimumab and other high-volume categories.

Understanding PBM economics — not just as a theoretical framework, but at the contract and affiliate level — is a prerequisite for building a market access strategy that actually works.

Ignoring the ASP Variability Problem

Average Sales Price (ASP) variability is one of the most underappreciated risks in biosimilar commercialization, particularly for hospital and clinic-administered products reimbursed under Medicare Part B.

ASP is calculated on a lagging basis and is sensitive to pricing decisions made across the competitive set. As new biosimilars enter a reference biologic's market and price aggressively, ASP can decline faster than your cost structure can accommodate. The HHS ASPE confirmed that biosimilar competition reduced Medicare Part B spending by 62% in 2023 — validating the scale of ASP compression in competitive biosimilar classes. 

Adding further complexity: the 2026 Medicare Physician Fee Schedule final rule introduced significant new ASP reporting methodology changes effective 01/01/2026, altering how ASP is calculated and reported across the competitive set. Companies that have not updated their reimbursement models to reflect these methodology changes are working from incorrect assumptions.

Model multiple ASP scenarios — including a scenario where a late entrant prices 40–50% below you — and build your cost of goods and gross margin targets around those scenarios, not the optimistic case.

Underinvesting in the Evidence Package

Payers in 2026 are not buying on price alone. They are asking for real-world evidence, comparative effectiveness data, and pharmacovigilance records that demonstrate the biosimilar performs as expected in the real world — not just in clinical trials.

The Consolidated Appropriations Act of 2026, signed on 03/02/2026, introduces the most significant PBM reforms in a decade — prohibiting rebate-linked compensation in Medicare Part D and requiring enhanced transparency and standardized reporting on formulary placement rationale. 

It is important to note that these reforms take effect in 2028–2029, not immediately. But the strategic signal is clear: the financial incentives that allowed PBMs to exclude biosimilars in favor of rebate-paying reference biologics are being structurally dismantled. Biosimilar manufacturers who are building their evidence packages, payer relationships, and formulary access strategies now will be best positioned when those reforms fully take effect.

Your evidence generation strategy should be running in parallel with your clinical program — not starting after approval.

Building a Reimbursement Strategy in a Vacuum

Reimbursement strategy for biosimilars is not a standalone workstream. It intersects with your pricing strategy, your patient services model, your specialty pharmacy relationships, and your medical affairs function. Companies that build these workstreams in silos consistently underperform on access metrics in the first twelve to eighteen months post-launch.

The fix is organizational: appoint a single executive accountable for the full market access ecosystem — pricing, contracting, formulary, reimbursement, and patient services — and give that person a seat at the leadership table from day one of commercial planning.

What Good Looks Like

The biosimilar companies executing market access well in 2026 share four characteristics:

• They started payer engagement years before launch — not at BLA submission

• They built scenario-based economic models that stress-tested ASP compression, rebate dynamics, and the new private-label PBM competitive threat

• They invested in real-world evidence programs alongside clinical development, not after approval

• They treated market access as a CEO-level priority — not a commercial function hand-off

The market is there. The science is proven. The gap between winning and losing in biosimilars in 2026 is almost entirely an execution and strategy gap.

At Katogen, we bring deep operator experience in product strategy, market access design, and commercial execution — grounded in 35+ years of hands-on biopharma leadership, including building a complex generics businesses from the ground up.

What the 2026 Biopharma M&A Surge Gets Wrong About Integration

USD228 billion in announced global biotech deals in 2025, up 73% from 2024. ING forecasts that pharma M&A activity will continue to accelerate in 2026, driven by the looming patent cliff and lower interest rates. The patent cliff — now estimated at USD 200–300 billion — is forcing large acquirers to move fast and move often.

That urgency is creating a boom. It is also creating a wave of integration failures that will take years to fully surface.

I have completed 17 acquisitions across my career. I have been on both sides of the table — as the acquirer and as the acquired. And I can tell you with conviction: the deals that fail do not fail because of bad science or wrong pricing. They fail because integration is treated as a post-close project rather than a pre-close strategy.

Here is what the current M&A surge is getting wrong.

Failure Mode 1: Diligence Ends at the Data Room

The standard biopharma M&A diligence process is designed to answer one question: is the asset real? It interrogates clinical data, IP position, regulatory history, and financial projections. What it rarely does is answer the harder question: can we actually combine these two organizations and make the math work?

AbbVie's acquisition of Stemcentrx for USD 5.8 billion — and the subsequent failure of Rova-T — is the canonical cautionary tale. The science looked compelling at the ESMO data. The deal thesis was defensible. But the operational and clinical execution complexity of integrating a novel modality asset into a large pharmaceutical infrastructure was systematically underestimated. 

The lesson is not that the deal was wrong. It is that capability diligence was not done with the same rigor as asset diligence. Before you close, you need to answer: Do we have the manufacturing infrastructure, the regulatory expertise, and the commercial execution capability to make this asset succeed inside our organization? If the answer is no that is not a deal-breaker — but it changes the integration plan, the timeline, and the capital requirements materially.

Failure Mode 2: Integration Planning Starts at Close

This is the single most common and most expensive mistake in biopharma M&A. Companies spend six to twelve months in diligence and negotiation, then treat the one hundred days post-close as the starting gun for figuring out how to combine two organizations.

By the time the ink is dry, you have already lost three to six months of integration runway. Key talent at the acquired company — who were waiting to see how the deal shook out — have started taking calls from recruiters. The regulatory team has not been briefed. The supply chain assumptions built into the deal model have not been stress-tested against operational reality.

Integration planning must begin during diligence. Not a full plan — you do not have enough information yet. But the integration thesis, the organizational design principles, the first ninety-day priorities, and the talent retention strategy should all be in draft form before you sign.

Failure Mode 3: The CEO Steps Back After Close

The most value-destructive thing an acquiring CEO can do after a deal closes is delegate integration to a program management office and move on to the next priority.

I have seen this repeatedly. The PMO tracks milestones. The slide decks show green. Meanwhile, the cultures are not integrating, the key scientists are disengaged, and the commercial teams are operating in parallel rather than as a unified force.

Integration is not a project management problem. It is a leadership problem. The decisions that determine whether a deal creates or destroys value — which team leads the combined R&D organization, how you resolve conflicting regulatory strategies, where you consolidate manufacturing — require executive judgment, not Gantt charts.

As the acquiring CEO, your job for the first six months post-close is integration. Everything else is secondary.

The Framework That Works

Here is what separates value-creating deals from value-destroying ones:

• Define success before you sign. What does this deal look like 18 months post-close? If you cannot answer that with specifics — revenue, pipeline milestones, organizational structure, cost synergies realized — you are not ready to close.

• Build your integration team during diligence. The people who will run the integration should be in the data room, not introduced at the closing dinner.

• Retain talent with urgency. The first 30 days post-close are when you lose the people you cannot afford to lose. Have retention conversations early, personally, and with substance — not just platitudes about the exciting future ahead.

• Operate with a bias toward speed. Uncertainty is the enemy of retention, morale, and execution. Make decisions faster than feels comfortable. A wrong decision made quickly and corrected is better than the right decision made six months late.

The 2026 M&A surge will create enormous value for companies that are strategically prepared and operationally disciplined. It will destroy value for companies that confuse a signed term sheet with a completed strategy.

At Katogen, we work alongside executive teams through the full transaction lifecycle — from deal thesis to post-close integration — grounded in 35+ years of operator experience and 17 completed acquisitions.

Biopharma M&A in 2026 - What CEOs Must Know Before Their Next Deal

The deals are back. After years of constrained capital and cautious boards, biopharma M&A has returned with force. According to Bain & Company's Global M&A Report 2026, pharma deal value rose 79% in 2025 compared to 2024, with average deal size climbing more than 80%. ING forecasts M&A volume will increase another 15% in 2026, driven by the looming patent cliff and falling interest rates. 

But more deals does not necessarily mean better deals. And for CEOs navigating this environment - whether as buyers, targets, or simply trying to position their company for maximum optionality - the stakes have never been higher. Here is what the current moment demands.

The $200B Patent Cliff Is Driving Urgency - and Mistakes

The structural driver behind today's M&A surge is well understood - a USD200-236 billion patent cliff threatening to erode the revenue bases of the world's largest pharma franchises. Companies with blockbuster drugs going off-patent need new pipelines - and buying them is faster than building them. 

That urgency creates both opportunity and danger. Acquirers are under pressure to replace revenue, which can lead to decisions being made faster than their diligence processes can handle. Sellers, sensing leverage, may overstate pipeline value or obscure operational risks. The result - a market where the spread between value-creating and value-destroying deals is wider than ever.

If you are a CEO at a growth-stage biopharma company right now, the question is not whether M&A activity affects you. It does. The question is whether you are ready for it - and whether you understand how the rules of the game have changed.

The New M&A Playbook - Capabilities Over Blockbusters

The biggest strategic shift in biopharma M&A right now is the move away from chasing the next blockbuster toward acquiring capabilities - platforms, manufacturing know-how, delivery technologies, data infrastructure, and AI-enablers. Bain's analysis confirms this - buyers are increasingly inking deals that build out the entire drug development stack, not just adding pipeline assets. 

This has direct implications for how you value your own company, and how you evaluate targets:

• Platform value is real. If you have a novel drug delivery platform, a proprietary manufacturing capability, or a novel formulation technology, that has acquirer value beyond any single asset.

• Data and AI readiness are increasingly part of diligence. Acquirers are asking whether your development processes are AI-enabled. If they are not, expect that to be a discount factor.

From 17 acquisitions across my career, I can tell you - the deals that created the most value were never purely about the asset. They were about what the combined entity could do that neither party could do alone.

Biosimilars and Novel Modalities - The M&A Sub-Themes You Cannot Ignore

Two areas deserve particular attention for biopharma CEOs in 2026.

Biosimilars are entering a new regulatory era. The FDA's March 2026 draft guidance streamlines biosimilar development by removing certain pharmacokinetic (PK) study requirements - a move that could reduce development costs by up to USD20 million per program. This lowers barriers to entry, accelerates timelines, and is reshaping the competitive dynamics of the biosimilar market. For companies in this space, the strategic implication is clear - the window to establish manufacturing scale and market access infrastructure before the field gets more crowded is narrowing.

Novel modalities - cell and gene therapies, ADCs, RNA-based therapeutics - continue to command premium M&A valuations, but integration complexity is extreme. These are not assets you can plug into a traditional pharma commercial infrastructure. They require specialized manufacturing, differentiated reimbursement strategies, and regulatory expertise that many large acquirers are still building. That gap is where experienced advisory support pays for itself many times over.

Why Most Deals Fail to Create Value (And How to Be the Exception)

The uncomfortable truth in biopharma M&A is that most deals underperform. Not because the assets are bad, or the price is wrong, but because integration is treated as an afterthought.

Integration is not an HR project. It is a business-critical, CEO-level priority from the moment the term sheet is signed. The companies I have seen extract real value from acquisitions share three characteristics:

1. Integration planning begins during diligence, not after close. You cannot wait 90 days post-close to figure out how you are combining supply chains, regulatory teams, or commercial organizations.

2. The acquiring CEO is operationally involved. Delegating integration entirely to a PMO is a mistake. The cultural and operational decisions that determine whether a deal works or not require executive judgment, not project management.

3. They define success metrics before signing. What does a successful acquisition look like 18 months post-close? If you cannot answer that question with specifics before the deal is done, you are flying blind.

How to Position Your Company for M&A Optionality in 2026

Whether you are building toward an exit, a strategic partnership, or simply want to remain an independent acquirer, your positioning matters now. The market is moving. Here is what sophisticated acquirers are looking for when they look at you:

• Clean regulatory history. Outstanding CMC issues, Form 483 observations, or unresolved FDA correspondence are deal killers or significant discount factors. Address them before you need to.

• Reimbursement clarity. If your lead asset does not have a credible market access and reimbursement strategy, acquirers will price that uncertainty into their offer. Build the strategy now.

• Operational scalability. Can your supply chain, manufacturing, and quality systems handle 3x volume? If not, document the roadmap to get there.

• A narrative, not just a data room. The best M&A processes are won by companies that can tell a compelling, credible story about where they are going - not just where they have been.

The Bottom Line

The 2026 biopharma M&A environment rewards companies that are strategically prepared, operationally credible, and guided by advisors who have actually executed deals - not just modeled them. According to ZRG Partners, "biopharma's next wave will be built on capability, not cash alone." That is exactly right.

At Katogen, we bring 35+ years of operator experience - 17 acquisitions, USD4B+ raised, and CEO-level accountability across multiple biopharma builds and turnarounds - to every engagement. We do not consult from the outside. We work alongside leadership teams to navigate the decisions that matter.

If you are evaluating a transaction, preparing for a raise, or simply want to stress-test your current strategy, we would welcome the conversation.